Author(s): Bala MV, Zarkin GA
Abstract Share this page
Abstract In this paper, we examine the problems associated with using quality adjusted life years (QALYs) as the measure of effectiveness to evaluate interventions for acute conditions. We illustrate the way in which using commonly accepted benchmarks for costs per QALY, in order to adopt interventions for acute conditions, might result in decisions that are not consistent with maximizing net societal benefit. We suggest that an alternate methodology, such as willingness to pay, may be more appropriate to make allocation decisions for acute conditions. Copyright 2000 John Wiley & Sons, Ltd.
This article was published in Health Econ
and referenced in Journal of Stem Cell Research & Therapy